LAG3, TIM3 and TIGIT: New Targets for Immunotherapy and Potential Associations with Radiotherapy
The combination of immunotherapy and radiotherapy has demonstrated synergistic potential, especially when a combination of immune checkpoint inhibitors (ICIs) is administered. Cytotoxic T-Lymphocyte-Associated Protein-4 (CTLA-4) inhibitors and Programmed Death-Ligand 1 (PD-L1) inhibitors or Programm...
Saved in:
| Main Authors: | Camil Ciprian Mireștean, Roxana Irina Iancu, Dragoș Petru Teodor Iancu |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-04-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/32/4/230 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Insights into the mechanisms of serplulimab: a distinctive anti-PD-1 monoclonal antibody, in combination with a TIGIT or LAG3 inhibitor in preclinical tumor immunotherapy studies
by: Yizhou Zhang, et al.
Published: (2024-12-01) -
Promising immunotherapy targets: TIM3, LAG3, and TIGIT joined the party
by: Chenyu Lu, et al.
Published: (2024-03-01) -
Modern Radiotherapy for Head and Neck Cancers: Benefits and Pitfalls - a Literature Review
by: CAMIL CIPRIAN MIRESTEAN, et al.
Published: (2019-09-01) -
TIM-3 teams up with PD-1 in cancer immunotherapy: mechanisms and perspectives
by: Zhuohong Yan, et al.
Published: (2025-05-01) -
Delta-radiomics Entropy Based on Tumor Heterogeneity Concept – Response Predictor to Irradiation for Unresectable/recurrent Glioblastoma
by: Camil Ciprian MIRESTEAN, et al.
Published: (2022-12-01)